LGND Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$342.82median target· current $280.18 (+22.4%)9 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
49 articles · sorted by datePage 1 of 3 · 49 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio29.66Forward 32.05
EPS (TTM)$9.80825.0% YoY
Profit margin67.9%HEALTHCARE
Market cap$5.80BMid cap
Valuation
- Forward P/E
- 32.05
- PEG ratio
- 1.53
- P/B
- 5.93
- P/S (TTM)
- 19.95
- EV/EBITDA
- 19.84
Profitability & growth
- ROE (TTM)
- 22.0%
- Operating margin
- 13.5%
- Revenue growth YoY
- 33.7%
- Dividend yield
- —
- Beta
- 0.98
Last earnings
Aug 6, 2026 · Estimate $1.34 · Reported $2.22
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Ligand Pharmaceuticals Incorporated
Company profileLigand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 555 HERITAGE DRIVE, JUPITER, FL
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$5.80B
Shares outstanding$19.9M
52W high$326.63
52W low$156.91
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent